Get the Stockscreener App
17.10
0.29%
0.11
After Hours:
17.00
-0.10
-0.58%
Rallybio Corp stock is traded at $17.10, with a volume of 14,372.
It is up +0.29% in the last 24 hours and up +3.78% over the past month.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
See More
Previous Close:
$16.99
Open:
$17
24h Volume:
14,372
Relative Volume:
0.28
Market Cap:
$90.81M
Revenue:
$858.00K
Net Income/Loss:
$-7.82M
P/E Ratio:
-11.79
EPS:
-1.4503
Net Cash Flow:
$-27.59M
1W Performance:
+2.59%
1M Performance:
+3.78%
6M Performance:
+293.53%
1Y Performance:
+252.65%
1-Day Range:
$16.66
$17.29
1-Week Range:
$16.33
$17.35
52-Week Range:
$3.6701
$17.57
Rallybio Corp Stock (RLYB) Company Profile
Name
Rallybio Corp
Sector
Industry
Phone
203- 859-3820
Address
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
17.10 | 90.23M | 858.00K | -7.82M | -27.59M | -1.4503 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-07-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-17-23 | Initiated | H.C. Wainwright | Buy |
| Apr-10-23 | Initiated | Wedbush | Outperform |
| Dec-09-22 | Initiated | JP Morgan | Overweight |
| Feb-22-22 | Initiated | JMP Securities | Mkt Outperform |
| Aug-23-21 | Initiated | Cowen | Outperform |
| Aug-23-21 | Initiated | Evercore ISI | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
View All
Rallybio Corp Stock (RLYB) Latest News
Rallybio Company Profile & Introduction - Moomoo
Rallybio (NASDAQ:RLYB) Upgraded at Wall Street Zen - MarketBeat
Rallybio Corporation (RLYB) holders report 3.56% stake in Schedule 13G/A - Stock Titan
Cormorant Asset Management (RLYB) now reports 0% beneficial ownership of Rallybio - Stock Titan
Rallybio Corporation (NASDAQ:RLYB) Sees Large Drop in Short Interest - MarketBeat
Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A - Stock Titan
Rallybio Corp (NASDAQ: RLYB) Stock Price, News & Analysis - Kalkine
Rallybio Corp (RLYB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rallybio (NASDAQ:RLYB) Releases Earnings Results, Beats Estimates By $8.81 EPS - MarketBeat
Rallybio Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
FMR LLC reports 15% Rallybio Corp (RLYB) stake, including 5% fund holding - Stock Titan
Rallybio Corp 2Q 2026: Revenue $0 Net income $43.67M, EPS $7.53— 10-Q Summary - TradingView
Laurion Capital exits Rallybio (RLYB) position, reports 0% beneficial ownership - Stock Titan
Rallybio Corp (RLYB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rallybio Q1 2026 Earnings: Wider-than-Expected Loss as Development Costs PersistGeographic Revenue Trends - dars.gov.et
RLYB Q2'26 Earnings: revenue estimate is 0 USD - TradingView
RLYB|Rallybio Corp|Price:16.350|Chg%:+0.160 - TradingKey
Rallybio Corp (RLYB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Rallybio Corp (RLYB) Balance Sheet - TradingKey
Rallybio Corp (RLYB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rallybio Corporation (NASDAQ:RLYB) Sees Significant Decline in Short Interest - MarketBeat
RLYB|Rallybio Corp|Price:16.160|Chg%:-0.150 - TradingKey
Rallybio Market Sentiment - Benzinga España
Rallybio Corp (RLYB) Institutional Confidence - TradingKey
Rallybio Corp (RLYB) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
Rallybio Corporation Revenue Breakdown – FWB:33M0 - TradingView
Rallybio Corporation Revenue Breakdown – TRADEGATE:33M0 - TradingView
RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo – How Much Of The New Company Will Rallybio Shareholders Own? - Stocktwits
Rallybio Corp (RLYB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rallybio Corporation (RLYB) Surges 4%: Testing Resistance After Strong Upward MoveOvernight Profile - dars.gov.et
Rallybio Corporation (NASDAQ: RLYB) to merge and rebrand as Avenzo Therapeutics - Stock Titan
Total assets of Rallybio Corporation – FWB:33M0 - TradingView
Price to earnings forward of Rallybio Corporation – NASDAQ:RLYB - TradingView
Enterprise value to revenue forward of Rallybio Corporation – NASDAQ:RLYB - TradingView
Book value per share of Rallybio Corporation – FWB:33M0 - TradingView
Price to book forward of Rallybio Corporation – FWB:33M0 - TradingView
Long term debt to total equity ratio of Rallybio Corporation – FWB:33M0 - TradingView
Price to sales forward of Rallybio Corporation – FWB:33M0 - TradingView
Enterprise value to EBITDA forward of Rallybio Corporation – FWB:33M0 - TradingView
Net income before discontinued operations of Rallybio Corporation – FWB:33M0 - TradingView
Rallybio Corporation (RLYB) Edges Lower Amid Consolidation Near SupportPercent Below MA - dars.gov.et
Rallybio Corp (RLYB) director exercises stock options, lifts stake to 6,542 shares - Stock Titan
Rallybio Corporation (RLYB) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Rallybio (RLYB) Drifts Marginally Lower, Consolidating Between Key Support and ResistanceTrade Entry Signals - DonanımHaber
Adar1 Capital, Daniel Schneeberger buy $2.18m Rallybio stock By Investing.com - Investing.com Nigeria
Rallybio Corporation(NasdaqCM: RLYB) added to Russell Microcap Value Benchmark Index - marketscreener.com
Rallybio Corporation(NasdaqCM: RLYB) added to Russell Microcap Index - marketscreener.com
Rallybio Corporation(NasdaqCM: RLYB) added to Russell 3000E Index - marketscreener.com
RLYB stock hits 2-year highs after unveiling merger with Avenzo – how much of the new company will Rallybio shareholders own? - MSN
What's Driving Rallybio's Recent Surge and Investor Interest - Kavout | AI
Rallybio Corporation Actuals & Estimates (NASDAQ:RLYB) - TradingView
Rallybio Corp Stock (RLYB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rallybio Corp Stock (RLYB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
May 19 '26 |
Buy |
13.98 |
10,200 |
142,582 |
926,352 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 18 '26 |
Buy |
13.98 |
6,009 |
83,981 |
916,152 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 13 '26 |
Buy |
13.99 |
79,259 |
1,108,807 |
909,843 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 15 '26 |
Buy |
13.90 |
300 |
4,170 |
910,143 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 11 '26 |
Buy |
14.00 |
50,000 |
699,992 |
829,784 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 12 '26 |
Buy |
13.83 |
800 |
11,063 |
830,584 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 04 '26 |
Buy |
13.97 |
120,804 |
1,687,409 |
744,683 |
| ADAR1 Capital Management, LLC | 10% Owner |
May 05 '26 |
Buy |
14.00 |
35,101 |
491,260 |
779,784 |
| Lieber Jonathan I | Chief Financial Officer |
Feb 23 '26 |
Sale |
5.06 |
789 |
3,992 |
4,115 |
2.67%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):